-> LabGenius discovers next-generation protein therapeutics using robotic automation, synthetic biology and machine learning.

London, UK – October 29, 2020 – LabGenius has closed an oversubscribed $15M extension round, led by Atomico, to support the company’s mission of dramatically improving the discovery process for new protein therapeutics.

The additional capital brings the company’s total Series A funding to $25M and will be used to increase investment into LabGenus’ underlying technology platform and product pipeline. As part of this financing, Atomico Partner Irina Haivas will join the board.

LabGenius’ platform which combines, into a closed loop, robotic automation, synthetic biology and machine learning enables the team to systematically search through billions of potential protein designs and rapidly test those that are predicted to be high performing. Ultimately, the company’s technology will help slash the time, cost and risk associated with developing new drugs.

-ends-

LabGenius is a leading machine learning-driven protein engineering company pioneering the discovery of next-generation therapeutics. The company’s discovery platform, EVA, integrates several bleeding-edge technologies drawn from the fields of machine learning, robotic automation and synthetic biology. Headquartered in London, UK, the LabGenius team includes experts in protein engineering, synthetic biology, software engineering, data science and robotic automation.

Atomico invests in ambitious tech founders at Series A and beyond with a particular focus on Europe, leveraging deep operational experience to supercharge their growth. Founded in 2006, Atomico has partnered with over 100 ambitious teams - including those at Supercell, Graphcore, Omio, Klarna, Lilium, MessageBird, Gympass and The Climate Corporation. Atomico's team of founders, investors and operational leaders have been responsible for global expansion, hiring and marketing at companies from Skype, Google and Twitter to Uber and Spotify. The firm currently has $2.7B in assets under management.

Atomico:

bryce@atomico.com, eleanor@atomico.com

LabGenius:

press@labgeni.us

Source: https://labgeni.us/series-a-extension